Steven Brugger, Affinivax CEO

Watch out, Pfiz­er: Affini­vax lands $226M in fund­ing to ad­vance Pre­vnar 13 ri­val as well as the rest of its pipeline

Affini­vax CEO Steven Brug­ger hit the clin­ic a cou­ple years ago with an un­con­ven­tion­al take on a pneu­mo­coc­cal vac­cine de­signed to de­throne Pfiz­er’s Pre­vnar …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.